Novo Nordisk Gets FDA Approval For Haemophilia Treatment
By Dominic Chopping
Denmark'sNovo Nordisk A/S (NOV), the world's largest maker of insulin, said Wednesday the U.S. Food and Drug Administration has approved its Biologics License Application for Novoeight, its treatment for chronic haemophilia.
-Awaiting the expiration of existing patents, Novo Nordisk plans to launch in the U.S. Novoeight shortly after Apr. 2015.
-At 0801 GMT shares traded 0.8% higher at DKK927.50.
-Write to Dominic Chopping at firstname.lastname@example.org; Twitter: @WSJNordics
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires 10-16-130418ET Copyright (c) 2013 Dow Jones & Company, Inc.